Immunovia AB (OSTO:IMMNOV) Cyclically Adjusted Revenue per Share: kr0.01 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:IMMNOV Immunovia AB OSTO:IMMNOV
44 GF Score
Price kr0.18
GF Value kr0.06
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Immunovia AB Cyclically Adjusted Revenue per Share?

Immunovia AB OSTO:IMMNOV +1.14% 44 Cyclically Adjusted Revenue per Share is kr0.01 as of Mar. 2026. GuruFocus rates OSTO:IMMNOV with a GF Score™ of 44/100 and a GF Value™ of kr0.06 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Immunovia AB's adjusted revenue per share for the three months ended in Mar. 2026 was kr0.001. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr0.01 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-28), Immunovia AB's current stock price is kr0.177. Immunovia AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was kr0.01. Immunovia AB's Cyclically Adjusted PS Ratio of today is 17.70.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Immunovia AB was 41.91. The lowest was 14.04. And the median was 20.15.


Immunovia AB  (OSTO:IMMNOV) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Immunovia AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.177/0.01
=17.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Immunovia AB was 41.91. The lowest was 14.04. And the median was 20.15.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Immunovia AB Cyclically Adjusted Revenue per Share Related Terms


Immunovia AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Immunovia AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunovia AB Cyclically Adjusted Revenue per Share Chart

Immunovia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.01 0.01

Immunovia AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.01 0.01

OSTO:IMMNOV vs TMO, DHR, IDXX: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Immunovia AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunovia AB Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Immunovia AB's Cyclically Adjusted PS Ratio falls into.


OSTO:IMMNOV
44GF Score
Immunovia AB OSTO:IMMNOV
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunovia AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Immunovia AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.001/133.5600*133.5600
=0.001

Current CPI (Mar. 2026) = 133.5600.

Immunovia AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.002 101.019 0.003
201609 0.000 101.138 0.000
201612 0.002 102.022 0.003
201703 0.001 102.022 0.001
201706 0.001 102.752 0.001
201709 0.001 103.279 0.001
201712 0.001 103.793 0.001
201803 0.002 103.962 0.003
201806 0.001 104.875 0.001
201809 0.002 105.679 0.003
201812 0.002 105.912 0.003
201903 0.001 105.886 0.001
201906 0.003 106.742 0.004
201909 0.002 107.214 0.002
201912 0.001 107.766 0.001
202003 0.000 106.563 0.000
202006 0.003 107.498 0.004
202009 0.001 107.635 0.001
202012 0.002 108.296 0.002
202103 0.002 108.360 0.002
202106 0.001 108.928 0.001
202109 0.006 110.338 0.007
202112 0.005 112.486 0.006
202203 0.003 114.825 0.003
202206 0.002 118.384 0.002
202209 0.006 122.296 0.007
202212 0.007 126.365 0.007
202303 0.009 127.042 0.009
202306 0.004 129.407 0.004
202309 0.009 130.224 0.009
202312 0.003 131.912 0.003
202403 0.003 132.205 0.003
202406 0.001 132.716 0.001
202409 0.002 132.304 0.002
202412 0.003 132.987 0.003
202503 0.000 132.825 0.000
202506 0.000 133.699 0.000
202509 0.000 133.480 0.000
202512 0.001 133.390 0.001
202603 0.001 133.560 0.001

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr0.01 mean?
Immunovia AB (OSTO:IMMNOV) has a Cyclically Adjusted Revenue per Share of kr0.01 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Immunovia AB and its competitors.
Is Immunovia AB's Cyclically Adjusted Revenue per Share too high?
Immunovia AB's current Cyclically Adjusted Revenue per Share is kr0.01. Overall, Immunovia AB has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immunovia AB's Cyclically Adjusted Revenue per Share compare to TMO and DHR?
Immunovia AB's Cyclically Adjusted Revenue per Share of kr0.01 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Immunovia AB and its competitors. Immunovia AB's current Cyclically Adjusted Revenue per Share is kr0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovia AB stock overvalued right now?
Based on GuruFocus' analysis, Immunovia AB (OSTO:IMMNOV) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.06, compared to a current price of kr0.18 — trading 195% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr0.01. Immunovia AB's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Immunovia AB (OSTO:IMMNOV), the current Cyclically Adjusted Revenue per Share is kr0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immunovia AB (OSTO:IMMNOV) Overvalued in 2026?

Based on GuruFocus' analysis, Immunovia AB stock appears to be overvalued. The current stock price of kr0.18 is trading 195% above its estimated GF Value™ of kr0.06. GuruFocus considers Immunovia AB to be Significantly Overvalued.

Key valuation signals for OSTO:IMMNOV:

  • Cyclically Adjusted Revenue per Share: kr0.01
  • GF Value™: kr0.06 vs. price of kr0.18 (195% above fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the OSTO:IMMNOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Immunovia AB Business Description

Other Exchanges 0G8X:UK
Address Scheelevagen 8, Medicon Village, Lund, SWE, 223 63
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
44GF Score

Get the complete analysis for OSTO:IMMNOV

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.18
Price
kr0.06
GF Value